Twenty-six drug manufacturers were sued on Wednesday by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices.
“Globally, growth-stage capital has tightened. As a result, many firms, especially those in deep tech, find it harder to raise the larger and longer-term...